|
| 37423386 | Thombosis, major bleeding, and survival in COVID-19 supported by veno-venous extracorporeal membrane oxygenation in the first vs second wave: a multicenter observational study in the United Kingdom. | | 2023 |
| 36148887 | Bleeding and thrombotic complications and their impact on mortality in patients supported with left ventricular assist device for cardiogenic shock. | Perfusion (United Kingdom) | 2023 |
| 36318961 | Frequency and Clinical Significance Anti-PS/PT Antibodies in Patients with Antiphospholipid Syndrome-Single Centre Observational Study in the United Kingdom. | Seminars in Thrombosis and Hemostasis | 2023 |
| 36437688 | The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial. | British Journal of Clinical Pharmacology | 2023 |
| 37647632 | The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140â¿¿214 UK Biobank participants. | Blood | 2023 |
| 37611622 | Safety and Efficacy of Therapeutic Anticoagulation with Subcutaneous Unfractionated Heparin in Patients with Renal Failure. | | 2023 |
| 37202865 | Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: Multicentre observational study in the UK. | | 2023 |
| 36574369 | Humanistic burden of problem joints for children and adults with haemophilia. | | 2023 |
| 37011710 | von Willebrand factor binds to angiopoietin-2 within endothelial cells and after release from Weibel-Palade bodies. | | 2023 |
| 36877609 | An expert consensus to define how higher standards of equitable care for von Willebrand disease can be achieved in the UK and Republic of Ireland. | | 2023 |
| 36812433 | Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. | | 2023 |
| 36700506 | Traumatic coagulopathy in the older patient: analysis of coagulation profiles from the Activation of Coagulation and Inflammation in Trauma-2 (ACIT-2) observational, multicenter study. | J Thromb Haemost | 2023 |
| 36674847 | Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. | | 2023 |
| 35065219 | Practical treatment guidance for cancer-associated thrombosis - Managing the challenging patient: A consensus statement. | | 2022 |
| 35846208 | Complement activation during cardiopulmonary bypass and association with clinical outcomes. | | 2022 |
| 35846054 | Impact of aspirin on bleeding and blood product usage in off-pump and on-pump coronary artery bypass graft surgery. | | 2022 |
| 36163263 | Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial. | Critical Care | 2022 |
| 35645034 | Thrombophilia testing: A British Society for Haematology guideline. | British Journal of Haematology | 2022 |
| 35882249 | Lupus Anticoagulant and Cardiopulmonary Bypass. | Seminars in Thrombosis and Hemostasis | 2022 |
| 35677030 | Seroprevalence to adeno-associated virus type 6 in people with hemophilia B from a UK adult cohort. | Research and Practice in Thrombosis and Haemostasis | 2022 |
| 35989136 | Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations. | Vaccine | 2022 |
| 35979588 | The Cost of Von Willebrand Disease in Europe: The CVESS Study. | Clinical and Applied Thrombosis/Hemostasis | 2022 |
| 36408296 | Cerebral vein thrombosis after ChAdOx1 nCov-19 vaccination: Long-term outcome of four patients. | Research and Practice in Thrombosis and Haemostasis | 2022 |
| 35339117 | Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. | Haemophilia | 2022 |
| 35294811 | Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. | New England Journal of Medicine | 2022 |
| 34622443 | Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. | British Journal of Haematology | 2022 |
| 35033063 | Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel. | BMC Medical Genomics | 2022 |
| 34388841 | Impact of Thrombosis and Bleeding in Patients with Severe COVID-19 versus Other Viral Pneumonias in the Context of Extracorporeal Membrane Oxygenation. | Seminars in Thrombosis and Hemostasis | 2022 |
| 34500500 | Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UKâ¿¿-â¿¿a multicentre observational study. | British Journal of Haematology | 2022 |
| 34654053 | Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. | Blood advances | 2022 |
| 34588182 | Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination. | Journal of Neurology, Neurosurgery and Psychiatry | 2022 |
| 34532629 | Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis. | Research and Practice in Thrombosis and Haemostasis | 2021 |
| 33482676 | Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19). | Seminars in Thrombosis and Hemostasis | 2021 |
| 33525040 | Outcome of Major Hemorrhage at a Major Cardiothoracic Center in Patients with Activated Major Hemorrhage Protocol versus Nonactivated Protocol. | Seminars in Thrombosis and Hemostasis | 2021 |
| 33570647 | ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. | Blood advances | 2021 |
| 33521654 | Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis. | Lancet Rheumatology, The | 2021 |
| 33834859 | Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study. | J Am Heart Assoc | 2021 |
| 33662796 | Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. | Thromb Res | 2021 |
| 34351721 | Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. | N Engl J Med | 2021 |
| 34351722 | Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. | N Engl J Med | 2021 |
| 34184164 | COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. | Angiogenesis | 2021 |
| 34132386 | The clinical course of COVID-19 in pregnant versus non-pregnant women requiring hospitalisation: results from the multicentre UK CA-COVID-19 study. | British Journal of Haematology | 2021 |
| 33496750 | von Willebrand disease: proposing definitions for future research. | Blood advances | 2021 |
| 33190022 | Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype. | Thrombosis Research | 2021 |
| 32578345 | von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis. | Haemophilia | 2021 |
| 33236402 | Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID-19 while we are awaiting the results of clinical trials? | British Journal of Haematology | 2021 |
| 33075181 | Blocking von Willebrand factor free thiols inhibits binding to collagen under high and pathological shear stress. | Journal of Thrombosis and Haemostasis | 2021 |
| 33278841 | The heparin-von Willebrand factor interaction and conventional tests of haemostasis - the challenges in predicting bleeding in cardiopulmonary bypass. | British Journal of Haematology | 2021 |
| 34607867 | Relationship between anaemia, coagulation parameters during pregnancy and postpartum haemorrhage at childbirth: a prospective cohort study. | BMJ Open | 2021 |
| 34378280 | Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. | Haemophilia | 2021 |